AquaBounty Technologies, Inc. Form 10-K Annual Report

• This document is an annual report filed with the United States Securities and Exchange Commission pursuant to the Securities Exchange Act of 1934.
• The registrant is a publicly traded company with common stock valued at a par value of $0.001 per share.
• The filing includes specific regulatory check marks regarding the company's status as a reporting entity, including its classification as a smaller reporting company or emerging growth company.
• As of March 2, 2018, the company reported having over 12.5 million shares of common stock outstanding.
• The report incorporates by reference specific portions of the registrant's 2018 Proxy Statement for its upcoming Annual Meeting of Shareholders.

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).

• The document outlines the fiscal year 2017 financial report structure, covering market risks, corporate governance, and executive compensation.
• A significant portion of the report is dedicated to forward-looking statements regarding future financial positions and business strategies.
• The company details specific operational goals, including the commercialization of fish products and the transition to land-based production systems.
• Regulatory hurdles are highlighted, specifically mentioning the potential lifting of an FDA Import Alert and the issuance of labeling guidance.
• Management acknowledges that these predictions are based on current assumptions and involve significant risks that could cause actual results to differ.

These forward-looking statements include statements that are not historical facts, including statements regarding management’s expectations for future financial and operational performance and operating expenditures, expected growth, and business outlook; the nature of and progress toward our commercialization plan; the future introduction of our products to consumers; the countries in which we may obtain regulatory approval and the progress toward such approvals; any continued backing by our majority shareholder, Intrexon Corporation (“Intrexon”); the volume of eggs or fish we may be able to produce; the timeline for our production of saleable fish; the expected advantages of land-based systems over sea cage production; the validity and impact of legal actions; the potential for lifting of the FDA Import Alert and the issuance of labeling guidance; the completion of renovations at our new hatchery facility and the construction of a pilot-scale grow-out unit; and the establishment of a larger-scale grow-out facility.

• The document outlines expectations for the AquAdvantage Salmon product, including its anticipated market benefits and regulatory path.
• Management details financial projections regarding future revenue, operating results, and the necessity of raising additional capital.
• The company highlights significant uncertainties surrounding market acceptance of genetically engineered fish and the protection of intellectual property.
• Investors are cautioned that actual results may differ materially from projections due to emerging risks and the inherent unpredictability of the industry.
• AquaBounty explicitly declines any obligation to update these forward-looking statements as new information or future events develop.

We may not actually achieve the plans, intentions, or expectations disclosed in our forward-looking statements, and you should not place undue reliance on our forward-looking statements.

• AquaBounty Technologies is a biotechnology firm focused on increasing productivity in the aquaculture market through genetic modification.
• The company's flagship product, AquAdvantage Salmon, has received regulatory approval for production and consumption from both the FDA and Health Canada.
• AquAdvantage Salmon represents a historic milestone as the first genetically modified animal approved for human consumption.
• The company plans to utilize land-based, contained freshwater systems to establish fish farms near major urban demand centers.
• By producing salmon domestically, the company aims to reduce the United States' heavy reliance on billions of dollars in imported Atlantic salmon.

Although genetically modified crops have been accepted by consumers in the United States and South America for some time, AquAdvantage Salmon is the first genetically modified animal to be approved for human consumption.

• The FDA currently prohibits the import of AquAdvantage Salmon into the United States until specific labeling guidance is finalized.
• The company has experienced increasing net losses annually since 2015 and expects to continue incurring losses for the foreseeable future.
• Management is pursuing international regulatory approvals in Brazil, Argentina, China, and Chile to expand their market reach.
• The global aquaculture market was valued at $176.5 billion in 2017 and is projected to reach $219.4 billion by 2022.
• Salmon market prices are highly volatile due to a long production cycle of up to three years and a very short fresh shelf life of two to three weeks.

The daily spot (farm-gate or wholesale market) price for Atlantic salmon is very volatile due to the species’ long production cycle, which typically ranges between two and three years, and its short shelf life, which typically ranges between two and three weeks.

• The Atlantic salmon industry has seen significant consolidation as major producers in Norway, Chile, and Canada seek cost advantages and navigate regulatory hurdles.
• Despite record imports of 619 million pounds in 2016, the United States domestic salmon farming industry has contracted due to environmental concerns and foreign competition.
• U.S. seafood consumption significantly trails other proteins like chicken and beef, as well as European seafood consumption levels.
• Activist groups have pressured major retailers to reject genetically modified salmon, though producers believe wholesale demand will remain robust.
• FDA approval and consumer surveys suggest a majority of the public is willing to purchase genetically engineered seafood if it is deemed safe by regulators.
• Internal data indicates that while AquAdvantage Salmon grow faster in early stages, they do not reach a larger final size than conventional salmon.

The Atlantic salmon farming industry in the United States contracted significantly beginning in the 1990s in the face of environmental concerns and lower costs of production from foreign sources, notably Chile.

• AquAdvantage Salmon offers a 25% better feed conversion rate and a lower carbon footprint compared to conventional Atlantic salmon.
• Traditional open sea-cage farming is highly vulnerable to costly diseases like infectious salmon anemia and parasitic sea lice.
• Land-based Recirculating Aquaculture Systems (RAS) utilize ozone and ultraviolet radiation to isolate fish from environmental pathogens.
• A 2009 virus outbreak at a Prince Edward Island facility was successfully eradicated through rigorous screening and biosecurity upgrades.
• The use of RAS technology significantly reduces the need for vaccines, antibiotics, and pesticides in salmon production.

RAS facilities employ sophisticated water treatment technology including the use of ozone, salt treatment, and ultraviolet radiation to kill potential bacterial, fungal, or viral pathogens that might enter the system.

• Recirculating Aquaculture Systems (RAS) provide superior biosecurity and environmental control compared to traditional open-sea cage farming.
• AquAdvantage Salmon are genetically modified to reach marketable size in 18 to 20 months, nearly half the time required for conventional Atlantic salmon.
• The genetic modification utilizes a growth hormone gene from salmon and a promoter from the ocean pout to ensure consistent growth during early development.
• Land-based production reduces environmental risks such as pathogen exposure and the need for antibiotics while improving feed conversion by 25%.
• Locating inland facilities closer to major markets aims to reduce transportation costs and the overall carbon footprint of salmon production.

The presence of pathogens in an uncontrolled environment is a universally accepted fact in human and animal health.

• The company is establishing two initial production facilities in Prince Edward Island and Indiana to prove economic viability and consumer acceptance.
• Future commercialization may include selling fertilized eggs, licensing technology to other growers, or expanding proprietary land-based farming operations.
• AquAdvantage Salmon offers a 25% better feed conversion rate and faster growth, potentially allowing for premium egg pricing or lower production costs.
• Global expansion plans target major fish farming markets including Panama, Argentina, Brazil, China, and Chile, pending regulatory approvals.
• Research and development timelines for new fish products are projected to extend beyond ten to fifteen years due to regulatory and development complexities.

While no pricing structure has been set, we believe that the cost savings associated with AquAdvantage Salmon resulting from the ability to spread fixed costs over a greater number of fish and reduced grow-out time will allow AquAdvantage Salmon eggs to sell at a premium to standard Atlantic salmon eggs.

• The salmon distribution network is shifting toward consolidation, with large fish-farming companies increasingly selling directly to major retail and food service chains.
• United States regulation of genetically modified products is split between the USDA for plants and the FDA for animals under the Coordinated Framework.
• The FDA regulates genetically engineered animals through the Federal Food, Drug, and Cosmetic Act, requiring a rigorous pre-approval review process.
• AquaBounty began its regulatory journey in 1995, navigating a period where no defined framework for genetically engineered animals yet existed.
• The approval process involves a phased submission of technical data covering molecular characterization, phenotypic durability, and environmental safety.

At that time, there was no defined regulatory framework for the regulation of genetically engineered animals.

• The CVM confirmed the molecular characterization of the genetically engineered salmon was adequate by mid-2008.
• Multiple technical reviews including phenotypic characterization and food safety assessments were completed and validated by the FDA by late 2010.
• The FDA concluded that the AquAdvantage Salmon is as safe as conventional salmon with a reasonable certainty of no harm from consumption.
• A public meeting of the Veterinary Medicine Advisory Committee was convened in September 2010 to provide an independent scientific review of the FDA's findings.
• The advisory committee addressed four critical questions regarding animal safety, consumer safety, environmental impact, and the effectiveness of the growth gene.

Following this process, the FDA concluded that AquAdvantage Salmon “is as safe as food from [conventional] salmon, and that there is a reasonable certainty of no harm from consumption of food” from AquAdvantage Salmon.

• The Veterinary Medicine Advisory Committee (VMAC) found the genetically engineered salmon to be biologically equivalent to traditional Atlantic salmon and safe for consumption.
• Extensive physical barriers at production facilities in Prince Edward Island and Panama were deemed sufficient to mitigate potential environmental impacts from escapes.
• After years of public comment periods and environmental assessments, the FDA issued a formal Finding of No Significant Impact (FONSI) in late 2015.
• The FDA's final approval of the New Animal Drug Application (NADA) in November 2015 included guidance for voluntary rather than mandatory labeling of the product.
• Immediately following the approval, a coalition of NGOs filed a lawsuit against the FDA, alleging a failure to properly analyze risks to wild salmon populations.

Following the FDA approval, in April 2016, a coalition of NGOs sued the FDA for their approval of AquAdvantage Salmon.

• Legal claimants are seeking to vacate the FDA's approval of AquAdvantage Salmon, arguing the agency lacks jurisdiction over genetically modified animals.
• The 2016 Omnibus Appropriations Act forced the FDA to implement an Import Alert on the salmon until final labeling guidance for GMO products is established.
• Despite the labeling controversy, the FDA and Health Canada have both concluded that the salmon is as safe and nutritious as traditional Atlantic salmon.
• Operating sites in Panama and Canada must be registered and inspected by the FDA as drug manufacturing establishments because the genetic modification is regulated as a drug.
• Environment Canada ruled that the production of sterile, all-female eggs in contained facilities poses no harm to the environment or human health.

At this time, there can be no certainty as to when or if the Import Alert will be lifted or when the FDA will finalize its labeling guidance.

• Canadian courts upheld the decision to allow commercial production of AquAdvantage Salmon, dismissing challenges from environmental groups.
• The company resolved regulatory compliance issues in Panama and is now seeking approval for commercial sale and consumption in that market.
• Field trials for the genetically modified salmon are currently expanding into South American markets, specifically Argentina and Brazil.
• Future U.S. production will require site-specific FDA approvals and environmental assessments that may take years and involve significant costs.
• The company has secured its own egg supply by purchasing a farm on Prince Edward Island to support production for the next five years.

We expect that we will incur costs to comply with these environmental and regulatory requirements, which could take several years to complete for each production site.

• The company transitioned from a royalty-based license to a perpetual, royalty-free global right for genetically modified salmonid technology after a one-time payment of $140,000.
• Despite the expiration of key patents, the company relies on trade secrets and complex regulatory hurdles to maintain a competitive barrier against potential rivals.
• A new U.S. patent was granted for a molecular sterility system that, while not currently required by regulators, may be essential for future approvals.
• Current production of AquAdvantage Salmon eggs is limited to a seasonal window, but a new facility at Rollo Bay is expected to enable year-round production.
• While no direct competitor exists for growth-enhanced genetically modified salmon, the company must compete against established multinational corporations selling conventional salmon.

Despite the expiration of the patent for the licensed technology, we believe that the degree of know-how in the molecular modification process and the regulatory timescales associated with approval of genetically modified fish would present significant barriers to competition.

• The company maintains a dedicated research and development team of nineteen employees primarily based at their hatchery on Prince Edward Island.
• A strategic collaboration with Intrexon provides access to advanced technology platforms like UltraVector for developing genetically modified finfish traits.
• Financial arrangements with Intrexon include a profit-sharing model where the company pays 16.66% of gross profits from developed products.
• Current research projects focus on precise genome engineering and the use of germ cells to accelerate the development of new traits in fish.
• Future product goals include a second generation of AquAdvantage Salmon with 100% sterility and faster-growing rainbow trout.
• Research and development expenditures are projected to increase by 5% to 10% annually as new projects are initiated.

The second project, which commenced in September 2013, is a research effort to determine if the use of germ cells to perform gene modification is effective in reducing the time required to develop new traits in finfish.

• The company maintains a diverse geographic footprint with facilities in Massachusetts, Panama, Prince Edward Island, and Indiana.
• A significant transition in public listing occurred in 2017 when the company moved from the London Stock Exchange's AIM to the Nasdaq Capital Market.
• Major capital infusions have been driven by Intrexon, the controlling shareholder, alongside a 2018 public offering that raised over $10 million.
• Management is exploring multiple revenue streams, including direct fish production, egg sales to Atlantic salmon farmers, and licensing agreements.
• As an 'emerging growth company' under the JOBS Act, the firm utilizes various reporting exemptions and extended timelines for accounting standards.

Management is evaluating several paths to revenue generation that follow different timelines, including production of our fish at our existing farm sites in Panama, Indiana, Rollo Bay, and additional facilities in North America.

• The company has elected to operate as an emerging growth company, allowing it to delay the adoption of certain accounting standards.
• This status provides exemptions for up to five years or until the company reaches specific financial milestones, such as $1.07 billion in annual revenue.
• The decision to utilize the extended transition period for accounting compliance is irrevocable under Section 107 of the JOBS Act.
• The executive leadership team consists of seasoned professionals with extensive backgrounds in animal health, biotechnology, and financial management.
• Key leaders include CEO Ronald L. Stotish, who has over 40 years of experience in the commercialization of animal health products.

Our financial statements may therefore not be comparable to those of companies that comply with such new or revised accounting standards.

• The company highlights the specialized expertise of its leadership, including Dr. Rojas in aquaculture health and Christopher Martin in corporate law.
• AquaBounty has incurred significant net losses totaling approximately $108.5 million from its inception through September 2017.
• The firm is currently expanding its production capacity through facility construction in Rollo Bay and renovations in Albany, Indiana.
• Significant revenue is not anticipated until late 2019, and the company warns of the ongoing need for substantial additional capital.
• Management explicitly cautions investors that the company may never achieve profitability and that the trading price of common stock could decline to zero.

If that were to happen, the trading price of our common stock could decline, and you could lose all or part of your investment.

• The company anticipates a critical need for additional funding to sustain operations and complete its development programs.
• Current revenue is limited to modest output from a Panama site, which is insufficient to cover multi-million dollar annual net losses.
• Future growth depends on FDA approval for new production facilities in Indiana and Rollo Bay, which remain subject to construction and regulatory delays.
• Expansion strategies include licensing technology or building new land-based facilities costing approximately $17 million per 1,000 metric tons of output.
• Raising capital may require relinquishing valuable rights to technology or diluting shareholder equity through new stock issuances.

These facilities have estimated construction costs of $17 million for each 1,000 metric tons of output.

• Regulatory approvals may come with onerous obligations or demands for costly additional data that delay market entry.
• Public perception and ethical concerns regarding genetically modified organisms pose a significant threat to product acceptance and revenue.
• Activist groups actively pressure retail food outlets and grocery chains to boycott genetically modified Atlantic salmon.
• Legal challenges from non-governmental organizations can result in judicial reviews and appeals that impede the commercialization process.
• Negative publicity and labeling campaigns may lead to increased trade restrictions and heightened regulatory scrutiny.

There is an active and vocal group of opponents to genetically modified organisms who wish to ban or restrict the technology and who, at a minimum, hope to sway consumer perceptions and acceptance of this technology.

• A coalition of NGOs filed a lawsuit against the FDA challenging its statutory authority to regulate genetically modified animals like AquAdvantage Salmon.
• Claimants argue the FDA failed to properly analyze ecological risks, specifically the potential for escaped GM salmon to threaten endangered wild stocks.
• The passage of the National Bioengineered Food Disclosure Standard ended the 'substantially equivalent' status that previously exempted the product from labeling.
• New federal and state labeling requirements may lead consumers to perceive the product as inferior or unsafe compared to traditional Atlantic salmon.
• Ongoing litigation and evolving international regulations pose significant financial risks and could delay the commercialization of the product.

Labeling requirements could cause consumers to view the label as either a warning or as an indication that AquAdvantage Salmon is inferior to traditional Atlantic salmon, which could negatively impact consumer acceptance of our product.

• The company faces significant costs and liabilities associated with complex federal, state, and international environmental and health regulations.
• Developing regulations for genetically modified animals are subject to sudden legislative changes that can override previous FDA approvals.
• Specific state-level bans in Washington, California, and Alaska limit the available geographic locations for production facilities.
• The commercial viability of the technology is at risk from potential broodstock destruction or the inadvertent spread of undetected diseases.
• New labeling requirements and import alerts have created delays in the commercialization of AquAdvantage Salmon despite prior regulatory clearances.

Such legislatively imposed review of a completed regulatory process could result in new restrictions on, or delays in, commercialization of our product in the United States.

• Concentrated broodstock facilities create a single point of failure where system damage could result in significant revenue loss.
• While land-based closed containment reduces exposure, the company remains vulnerable to disease outbreaks that necessitate costly biosecurity measures.
• The core patent for AquAdvantage Salmon expired in 2013, forcing a shift toward protecting proprietary technology through trade secrets and regulatory barriers.
• Enforcing intellectual property rights is described as an expensive and unpredictable process that risks having existing patents declared invalid or unenforceable.
• The company relies on confidentiality agreements with employees and collaborators to protect the 'know-how' that prevents competitors from entering the market.

Enforcing our intellectual property rights can be expensive and time consuming, and the outcome of such efforts can be unpredictable.

• Patent litigation outcomes are inherently unpredictable, and legal assertions of invalidity or unenforceability could strip the company of its market exclusivity.
• Even if patents are upheld, they may not be broad enough to prevent competitors from marketing similar products or using comparable manufacturing processes.
• Inadequate assignment of rights from inventors could allow third parties to obtain licenses, effectively precluding the company from enforcing its own patents.
• Global enforcement of intellectual property is inconsistent, as many foreign jurisdictions do not favor the protection of genetic engineering technologies.
• Cybersecurity breaches or infrastructure failures could lead to the theft of proprietary data, legal liability, and significant damage to the company's reputation.

Although we may believe that we have conducted our patent prosecution in accordance with the duty of candor and in good faith, the outcome following legal assertions of invalidity and unenforceability during patent litigation is unpredictable.

• The company faces significant competition from large multinational corporations with entrenched distribution channels and government support.
• Intellectual property theft or reverse engineering poses a major threat, particularly in countries with limited legal protections.
• The loss of key management personnel or highly skilled scientists could derail commercialization and research efforts.
• Rapid growth following product availability may strain operational resources and financial management systems.
• Strategic acquisitions and investments intended to bolster the business could have an adverse impact if they prove unsuccessful.

If our technologies or products were stolen, misappropriated, or reverse engineered, they could be used by other parties that may be able to reproduce our technologies or products using our technologies for their own commercial gain.

• Future acquisitions may lead to shareholder dilution, substantial debt, or the assumption of significant liabilities.
• Integrating new businesses poses operational risks, including the diversion of management's attention and potential loss of key employees.
• The company lacks extensive experience in managing integration processes, which could lead to financial strain and decreased employee morale.
• Existing agreements require the company to pay significant portions of future revenue to third parties, including a 10% royalty on specific research products.
• A collaboration with Intrexon mandates quarterly payments of 16.66% of gross profits for developed products and 50% of sublicensing revenue.

We do not have extensive experience in managing the integration process, and we may not be able to successfully integrate any businesses, assets, products, technologies, or personnel that we might acquire in the future without a significant expenditure of operating, financial, and management resources.

• The company faces significant financial exposure due to exchange rate fluctuations and the international distribution of its research personnel.
• Potential loss of government research grants and loans could force the company to fund projects entirely from limited cash resources, delaying product development.
• Overlapping stock ownership between AquaBounty and Intrexon management creates potential conflicts of interest regarding contractual disputes and commercial arrangements.
• Recent U.S. tax reform has altered the Internal Revenue Code, though the company expects minimal immediate impact on its cash taxes and net operating losses.
• International operations carry risks of expropriation of assets without fair compensation and governmental restrictions on the movement of funds.

This ownership overlap could create, or appear to create, potential conflicts of interest when AquaBounty management and directors and Intrexon management and directors face decisions that could have different implications for AquaBounty and Intrexon.

• The 2017 tax reform legislation introduces significant uncertainty regarding future tax liabilities and potential adverse effects on common stock holders.
• The company's ability to utilize net operating losses (NOLs) is restricted by Sections 382 and 383 of the Code, particularly if an ownership change occurs.
• Future shifts in stock ownership, many of which are beyond the company's control, could further impair the utility of existing tax attributes.
• Intrexon and Randal J. Kirk maintain a controlling interest of approximately 64%, granting them substantial influence over board nominations and corporate mergers.
• The concentration of ownership creates a risk that the interests of the controlling shareholder may diverge from those of minority investors.

Intrexon’s interests may not be consistent with those of our other shareholders.

• The significant ownership stake held by Intrexon may deter third-party acquisitions and negatively impact the stock price.
• There is no guarantee that an active trading market for the common stock will be sustained, potentially making it difficult for investors to sell shares.
• The stock price is expected to be highly volatile due to factors ranging from regulatory approval news to general economic conditions.
• The company does not intend to pay cash dividends, meaning investors must rely solely on stock appreciation for any return on investment.
• Stock performance is heavily dependent on the coverage and reports provided by independent securities and industry analysts.

As a result, absent payment of dividends, only appreciation of the price of our common stock, which may never occur, will provide a return to shareholders.

• The company's stock price and trading volume are vulnerable to fluctuations if financial analysts cease coverage or reduce reporting frequency.
• As an emerging growth company, the firm utilizes exemptions from various reporting requirements, including auditor attestations on internal controls and detailed executive compensation disclosures.
• The company has irrevocably elected to delay the adoption of new accounting standards, potentially making its financial statements less comparable to other public entities.
• Status as a controlled company allows for exemptions from Nasdaq's corporate governance rules, meaning the board does not require a majority of independent directors.
• Investors face risks that these reduced disclosures and governance protections may make the common stock less attractive and more volatile.

Our shareholders may not have the same protections generally available to shareholders of other Nasdaq listed companies because we are currently a “controlled company” within the meaning of the Nasdaq listing rules.

• The company operates as a controlled entity under Intrexon, which exempts it from certain Nasdaq requirements regarding independent board committees.
• Maintaining effective internal controls is critical to preventing fraud and ensuring the accuracy of financial reporting to avoid investor distrust.
• The Board of Directors holds the unilateral power to issue preferred stock, which could significantly dilute the voting power and value of common shares.
• Compliance with U.S. public company regulations like the Sarbanes-Oxley Act is estimated to cost approximately $400,000 annually.
• Transitioning out of emerging growth company status would further increase legal and financial compliance burdens on management.

The terms of one or more classes or series of preferred stock could dilute the voting power or reduce the value of our common stock.

• The company faces significant challenges in maintaining compliance with public company regulations and Nasdaq listing standards.
• Increased regulatory burdens have made it more expensive and difficult to secure director and officer liability insurance.
• Anti-takeover provisions and Delaware law may prevent shareholders from receiving a premium for their shares during a change of control.
• The board is authorized to issue blank check preferred stock to thwart potential takeover attempts.
• The company maintains physical operations across Massachusetts, Panama, Indiana, and Prince Edward Island to support its salmon production.

These provisions include: providing that the number of members of our board is limited to a range fixed by our bylaws; establishing advance notice requirements for nominations of candidates for election to our Board of Directors or for proposing matters that can be acted on by shareholders at shareholder meetings; and authorizing the issuance of “blank check” preferred stock, which could be issued by our Board of Directors to issue securities with voting rights and thwart a takeover attempt.

• A coalition of NGOs filed a lawsuit against the FDA challenging the approval of AquAdvantage Salmon on the grounds of statutory authority and environmental risk.
• The plaintiffs argue that the FDA failed to properly mitigate the risk of genetically modified salmon escaping and threatening endangered wild stocks.
• The company transitioned its stock listing from the London Stock Exchange's AIM to the Nasdaq Capital Market, voluntarily delisting from the former in 2017.
• Management maintains a policy of retaining all earnings to finance business growth rather than paying out cash dividends to stockholders.
• As of early 2018, the company reported over 12.5 million shares outstanding held by approximately 349 record holders.

The coalition, including the Centre for Food Safety and Friends of the Earth, claims that the FDA had no statutory authority to regulate genetically modified animals.

• The company issued over 3.6 million shares of unregistered common stock between late 2016 and early 2017 to settle debt and raise capital.
• A significant transaction involved issuing shares to Intrexon for approximately $25 million to fund general corporate operations.
• Financial reporting reflects a 1-for-30 reverse stock split that was implemented in January 2017 to adjust share calculations.
• The firm identifies as a biotechnology leader following the 2015 FDA approval of the AquAdvantage Salmon.
• Management is transitioning from regulatory milestones toward active commercial activities in approved global markets.

Our product is the AquAdvantage Salmon, which received FDA approval in 2015 as the first genetically modified animal available for sale for human consumption.

• The company has initiated its commercial plan by securing regulatory approval for new facilities in Prince Edward Island and acquiring assets in the United States.
• The first commercial sales of AquAdvantage Salmon occurred in June 2017 from a farm site in Panama, marking the first product revenue since 2008.
• Despite these sales, the company has incurred significant losses since inception and expects to remain unprofitable for the foreseeable future.
• Future growth depends on substantial capital requirements to fund land-based recirculating aquaculture systems and expanded research and development.
• Operational forecasting remains difficult due to the uncertain timing of production commencement at key facilities in Indiana and Rollo Bay.

We have incurred significant losses since our inception. We expect to continue to incur significant losses for the foreseeable future, and we may never achieve or maintain profitability.

• Future revenue growth is tied to regulatory approvals, facility capacity, and market acceptance of genetically engineered fish.
• The company transitioned from outsourcing research to Tethys back to an internal in-house research group to manage their broodstock.
• Research and development costs include salaries, laboratory supplies, and field trial operations, occasionally offset by government funding.
• General and administrative expenses cover executive salaries, regulatory compliance, and the maintenance of the Indiana facility.
• Financial reporting relies on U.S. GAAP and management's ongoing evaluation of estimates and judgments regarding assets and liabilities.

During 2015, we made the decision to reinstitute our in-house research group, and we have hired personnel to reestablish that function internally.

• The company maintains a 100% valuation allowance on deferred tax assets due to a consistent history of net losses since its inception.
• New revenue recognition standards were adopted to coincide with the first commercial sales of AquAdvantage Salmon in 2017.
• A $14.2 million acquisition of an Indiana facility was classified as an asset purchase rather than a business combination because it serves as a single input for production.
• Initial product revenue was generated from a single batch of fish shipped to Canada following regulatory approval in Panama.
• Management anticipates that future sales will remain infrequent and small in scale until the Indiana and Rollo Bay facilities reach full operational maturity in 2019.

Regulatory approval for the harvest and export of our fish from our Panama farm site was received during the year, and a batch of fish was sold and shipped to customers in Canada.

• Sales and marketing expenses fluctuated due to the completion of design fees for a land-based recirculating aquaculture facility.
• Research and development costs are expected to rise as the company develops its Rollo Bay site and seeks regulatory approval for new products.
• General and administrative expenses increased significantly due to higher compensation, professional fees, and legal challenges to regulatory approvals.
• The company has incurred continuous losses since its 1991 inception, resulting in an accumulated deficit of $108.5 million by the end of 2017.
• Liquidity has been maintained through private placements and public offerings of common stock, including a $25 million transaction with Intrexon.

We have incurred losses from operations since our inception in 1991, and, as of December 31, 2017, we had an accumulated deficit of $108.5 million.

• Intrexon significantly increased its stake by purchasing over 1.5 million shares and warrants for $5 million.
• Operating losses grew steadily from $7.0 million in 2015 to $9.3 million in 2017, driven by headcount additions and international expansion.
• The company shifted from minimal equipment spending to a massive $19.0 million investment in 2017 for site renovations in Indiana and construction in Rollo Bay.
• Working capital requirements were impacted by the establishment of new inventory in Panama and Canada alongside costs related to a public offering.
• Financing activities provided a critical cash influx, including $25.0 million from a private placement in 2017 and $10.6 million from a 2018 public offering.

Spending on operations increased in 2017 due to headcount additions and renovation costs at our Indiana site, offset by a reduction in legal fees.

• The company plans to allocate its existing cash toward farm sites in Indiana and Rollo Bay while continuing research and development.
• Future capital needs depend on regulatory approvals, construction costs, and the timing of legal challenges involving the FDA.
• To sustain operations, the company may seek financing through equity offerings, debt, or strategic alliances, which could dilute shareholder value or restrict business actions.
• Management maintains a 'going concern' status based on past successful offerings but admits that failure to secure new funding could lead to a total loss for stockholders.
• If funding is delayed, the company may be forced to slow or halt construction at its farm sites to conserve remaining cash resources.

If we cannot continue as a going concern, our stockholders would likely lose most or all of their investment in us.

• The company outlines significant contractual obligations, including royalty-based repayments for the AIF grant and profit-sharing agreements with Intrexon.
• Under the Exclusive Channel Collaboration, the company must pay Intrexon 16.66% of gross profits and 50% of sublicensing revenue for genetically modified finfish.
• New accounting standards for leases (ASU 2016-02) will soon require the recognition of lease liabilities and right-of-use assets on the balance sheet.
• Market risk exposure is primarily linked to fixed-rate debt, while foreign currency risk is managed through translation adjustments for the Canadian subsidiary.
• The company's primary functional currency is the U.S. Dollar, though operations in Canada, Panama, and Brazil introduce varied currency translation effects.

We agreed under the ECC to pay Intrexon, on a quarterly basis, 16.66% of the gross profits calculated for each developed product.

• The company maintains disclosure controls to ensure all required financial information is recorded, processed, and reported within SEC timeframes.
• Management, including the CEO and CFO, conducted a formal evaluation of the effectiveness of these disclosure procedures as of December 31, 2017.
• The report acknowledges that no control system, regardless of design, can provide absolute certainty and must be evaluated based on a cost-benefit relationship.
• Internal controls are designed to provide reasonable assurance regarding the reliability of financial statements and the prevention of unauthorized asset use.
• Using the COSO 2013 framework, management concluded that their internal control over financial reporting was effective at the end of the fiscal year.

Our management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives, and management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures.

• The company operates as an emerging growth company under the JOBS Act, allowing for reduced public reporting requirements.
• External auditors are not currently required to attest to the effectiveness of the company's internal control over financial reporting.
• Key governance and compensation details are omitted from this report and instead incorporated by reference from a future 2018 Proxy Statement.
• The company is exempt from holding nonbinding advisory votes on executive compensation or seeking approval for golden parachute payments.
• The report lists essential financial statements and legal exhibits, including the company's amended certificate of incorporation and bylaws.

We are an emerging growth company, as defined under the JOBS Act, and are therefore not required to provide certain disclosures regarding executive compensation required of larger public companies or hold a nonbinding advisory vote on executive compensation or obtain stockholder approval of any golden parachute payments not previously approved.

• The text lists various legal exhibits and agreements incorporated by reference into a formal registration statement.
• It details multiple equity incentive plans from 2006 and 2016, including specific stock option and restricted stock agreements.
• A significant portion of the documents highlights the deep financial and operational relationship between AquaBounty Technologies and Intrexon Corporation.
• The list includes diverse financial instruments such as common stock purchase warrants, promissory notes, and subscription agreements.
• International operations are evidenced by a lease and management agreement involving AquaBounty Panama and the Atlantic Canada Opportunities Agency.

Exclusive Channel Collaboration Agreement, by and between AquaBounty Technologies, Inc. and Intrexon Corporation, dated February 14, 2013.

• The text lists various employment agreements for key executives including Ronald Stotish, David Frank, and Alejandro Rojas.
• It details significant legal and operational documents such as collaborative research agreements and intellectual property licenses.
• The document references an asset purchase agreement with Bell Fish Company LLC and an amended lease in Panama.
• It outlines the regulatory compliance certifications required by the Sarbanes-Oxley Act of 2002 for the CEO and CFO.
• The section concludes with a power of attorney authorization for signing amendments to the Annual Report on Form 10-K.

KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints David A. Frank and Christopher Martin, as his or her attorneys-in-fact.

• The document presents an independent audit of AquaBounty Technologies' consolidated balance sheets and financial statements for the years 2016 and 2017.
• The auditors issued a clean opinion, stating that the financial statements fairly represent the company's position in accordance with U.S. GAAP.
• While the audit assessed risks of material misstatement, it did not include an official opinion on the effectiveness of the company's internal control over financial reporting.
• Financial data reveals a period of comprehensive loss and a significant increase in the number of common shares outstanding between 2016 and 2017.
• The report details the company's asset structure, including property, plant, equipment, and both definite and indefinite-lived intangible assets.

The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting.

• The document outlines consolidated statements of changes in stockholders' equity and cash flows for the years 2015 through 2017.
• AquaBounty Technologies was originally incorporated in 1991 to research antifreeze proteins before pivoting to transgenic salmon.
• The company secured exclusive rights to a gene construct that allows Atlantic salmon to grow substantially faster than traditional breeds.
• Regulatory milestones include FDA approval for US consumption in 2015 and Health Canada approval for sale in 2016.
• The corporate structure has expanded globally with subsidiaries in Canada, Panama, Brazil, and a dedicated aquaculture facility in Indiana.

In 1996, the Parent obtained the exclusive licensing rights for a gene construct (transgene) used to create a breed of farm-raised Atlantic salmon that exhibit growth rates that are substantially faster than traditional salmon.

• AquaBounty consolidated its various international subsidiaries and implemented a 1-for-30 reverse share split to restructure its equity.
• The company has faced persistent net losses and negative cash flows since its inception, leading to a formal evaluation of its ability to continue as a going concern.
• Management maintains that a 2018 public offering and the ability to delay construction projects provide sufficient liquidity for the immediate future.
• Financial reporting involves complex foreign currency translations across Canadian, Panamanian, Brazilian, and American entities.
• The company relies heavily on equity and debt financing to fund product development until commercial operations can achieve positive cash flow.

Using the proceeds of this financing and the ability to manage expenditures, including the slow down, delaying, or halting of construction projects at our farm sites, management has determined that the Company has sufficient funds to continue as a going concern.

• Inventory is measured at the lower of cost or net realizable value, which accounts for estimated selling prices minus completion and disposal costs.
• Intangible assets are categorized as definite-lived, such as patents and licenses, or indefinite-lived, such as trademarks which are not subject to amortization.
• Long-lived assets undergo annual impairment testing based on undiscounted cash flows and management's judgment of future revenue growth and discount rates.
• Revenue recognition is contingent upon a five-step process that includes identifying performance obligations and assessing the probability of collection.
• The Company utilizes the liability method for income taxes, recording deferred tax assets and liabilities based on temporary differences and enacted tax rates.

The Company’s impairment testing utilizes a discounted cash flow analysis that requires significant management judgment with respect to revenue and expense growth rates, changes in working capital, and the selection and use of the appropriate discount rate.

• The Company utilizes the Black-Scholes option pricing model to estimate the fair value of share-based payment awards for employees and non-employees.
• Net loss per share calculations exclude potential common shares from warrants and options because their inclusion would be anti-dilutive during loss periods.
• Business combinations are distinguished from asset purchases based on whether the acquired assets include a substantive process capable of creating outputs.
• Operational risks are primarily driven by regulatory decisions from the FDA, product development outcomes, and the ability to protect proprietary technologies.
• Financial risk management strategies include investing in short-term instruments with highly rated institutions and limiting foreign currency exposure in Canadian accounts.

If, however, the assets acquired include, at a minimum, an input and a substantive process that together significantly contribute to the ability to create outputs, then the transaction is deemed to be the purchase of a business.

• The company maintains significant investments in property and equipment, including the acquisition of the Atlantic Sea Smolt plant and the Bell Fish Company facility.
• Strategic acquisitions in Prince Edward Island and Indiana are being renovated to support the grow-out and harvesting of AquAdvantage Salmon.
• The purchase of the Indiana facility was classified as an asset purchase rather than a business acquisition because no workforce, inventory, or customers were transferred.
• Financial liabilities include long-term debt and accrued expenses, supported in part by historical research and development grants from the Atlantic Canada Opportunities Agency.
• The company holds a minority investment in A/F Protein, Inc., an entity with which it shares several common shareholders.

The facility and related assets acquired from Bell Fish Company LLC provide one input into the Company’s process for growing its product, and, accordingly, the purchase of the facility was accounted for as an asset purchase rather than the acquisition of a “business.”

• The Canadian subsidiary is obligated to repay research funding through royalties, though no such revenue was generated in 2016 or 2017.
• Major infrastructure projects at the Rollo Bay site were financed through agreements with the Atlantic Canada Opportunities Agency and Finance PEI.
• The company's majority shareholder, Intrexon, provided a convertible debt facility that was fully converted into common stock in late 2016.
• A significant 1-for-30 reverse share split was implemented in early 2017 to restructure the company's equity and outstanding share balances.
• Compensation for the Chairman of the Board includes restricted common stock that typically vests over a three-year period.

Revenue from the sale of AquaAdvantage Salmon are not subject to the royalty and the Company does not expect to commercialize products that would be subject to the royalty in the next five years.

• The company transitioned from its original 2006 Equity Incentive Plan to a new 2016 Plan following the expiration of the former's granting period.
• Equity awards including incentive stock options and restricted stock are available to directors, officers, employees, and consultants.
• Stock option fair values are calculated using the Black-Scholes model, incorporating factors like risk-free interest rates and historical price volatility.
• The company anticipates no dividend payments for the foreseeable future, resulting in an expected dividend yield of zero for valuation purposes.
• Financial reporting for 2017 was impacted by the enactment of the Tax Cuts and Jobs Act, which significantly revised U.S. tax law.

The expected dividend yield is because the Company has never paid a dividend and does not expect to do so for the foreseeable future.

• The 2017 Tax Act significantly altered the corporate landscape by reducing the income tax rate to 21% and implementing a modified territorial tax system.
• The Company recognized provisional tax impacts regarding domestic deferred tax assets while navigating the complexities of Staff Accounting Bulletin No. 118.
• Utilization of net operating loss carryforwards is restricted by annual use limitations triggered by ownership changes under Internal Revenue Code Sections 382 and 383.
• A full valuation allowance has been recorded against deferred tax assets because the Company has incurred losses since its inception and faces uncertainty regarding future profitability.
• Operational commitments include a significant five-year lease extension for office space in Maynard, Massachusetts, and a lease extension for a farm site in Panama.

Since the Company has incurred only losses from inception and there is uncertainty related to the ultimate use of the loss carryforwards and tax credits, a valuation allowance has been recognized to offset the Company’s deferred tax assets.

• The Company maintains various operating leases for office space in Brazil and other locations, with primary lease terms concluding in May 2018.
• Employment agreements with key officers include provisions for base pay, benefits, and mandatory severance payments under specific termination scenarios.
• Retirement savings plans are provided for both US and Canadian employees, including a 401(k) plan with discretionary employer contributions.
• A significant collaboration agreement with majority shareholder Intrexon grants the Company exclusive licenses to develop genetically modified finfish for human consumption.
• Financial terms of the Intrexon agreement require the Company to share gross profits and reimburse service costs, though no royalties were paid in the current period.

The ECC, which can be terminated by the Company upon 90 days’ written notice, grants the Company a worldwide license to use specified patents and other intellectual property of Intrexon in connection with the research, development, use, importing, manufacture, sale, and offer for sale of products involving DNA administered to finfish for human consumption.

• The Company has adopted new FASB guidance requiring management to evaluate and disclose substantial doubts regarding the entity's ability to continue as a going concern.
• New lease accounting standards will require the recognition of lease liabilities and right-of-use assets on the balance sheet based on discounted payment values.
• While current lease obligations are not expected to be material, future renewals or new agreements could significantly impact the Company's consolidated financial statements.
• The Company recently completed a public offering of common shares and warrants, with participation from Intrexon and an underwriter over-allotment option.
• Management asserts that all necessary recurring adjustments have been made to ensure a fair statement of the unaudited quarterly financial information.

Based on current leases in place, this is not expected to be material to the Company’s consolidated financial statements; however, such amounts may be material to the financial statements depending on terms of any lease renewals and other leases entered into.

• AquAdvantage Salmon is the first genetically modified animal approved for human consumption.
• AquaBounty plans land-based, contained freshwater farms near major urban demand centers to reduce reliance on imported Atlantic salmon.

Although genetically modified crops have been accepted by consumers in the United States and South America for some time, AquAdvantage Salmon is the first genetically modified animal to be approved for human consumption.

• AquAdvantage Salmon are engineered to reach marketable size in 18 to 20 months, nearly half the time required for conventional Atlantic salmon.
• The modification uses a salmon growth-hormone gene and an ocean-pout promoter to support consistent early growth.

The presence of pathogens in an uncontrolled environment is a universally accepted fact in human and animal health.

• The 2016 Omnibus Appropriations Act forced an FDA Import Alert on AquAdvantage Salmon until final GMO labeling guidance is established.
• Panama and Canada operating sites must be registered and inspected by the FDA as drug-manufacturing establishments because the genetic modification is regulated as a drug.

At this time, there can be no certainty as to when or if the Import Alert will be lifted or when the FDA will finalize its labeling guidance.

• After key patents expired, AquaBounty relies on trade secrets and complex regulatory hurdles to deter potential competitors.
• A new Rollo Bay facility is expected to shift AquAdvantage Salmon egg production from a seasonal window to year-round supply.

Despite the expiration of the patent for the licensed technology, we believe that the degree of know-how in the molecular modification process and the regulatory timescales associated with approval of genetically modified fish would present significant barriers to competition.

• AquaBounty incurred net losses totaling about $108.5 million from inception through September 2017.
• Management warns that the company may never achieve profitability and that common stock could decline to zero.

If that were to happen, the trading price of our common stock could decline, and you could lose all or part of your investment.